| Literature DB >> 27294958 |
Ana M Moura-da-Silva1, Michelle T Almeida2, José A Portes-Junior3, Carolina A Nicolau4, Francisco Gomes-Neto5, Richard H Valente6.
Abstract
Snake venom metalloproteinases (SVMPs) are abundant in the venoms of vipers and rattlesnakes, playing important roles for the snake adaptation to different environments, and are related to most of the pathological effects of these venoms in human victims. The effectiveness of SVMPs is greatly due to their functional diversity, targeting important physiological proteins or receptors in different tissues and in the coagulation system. Functional diversity is often related to the genetic diversification of the snake venom. In this review, we discuss some published evidence that posit that processing and post-translational modifications are great contributors for the generation of functional diversity and for maintaining latency or inactivation of enzymes belonging to this relevant family of venom toxins.Entities:
Keywords: enzyme inhibitor; hemorrhage; metalloproteinase; post-translational processing; snake venom
Mesh:
Substances:
Year: 2016 PMID: 27294958 PMCID: PMC4926149 DOI: 10.3390/toxins8060183
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 4.546
Figure 1Schematic representation of the most typical post-translational modification steps occurring during the maturation of nascent SVMPs: SVMP precursors are composed of signal-peptide/pre- (p), pro- (PRO), catalytic or metalloproteinase (CAT), disintegrin (DIS), disintegrin-like (DL), cysteine-rich (CR), and lectin-like (LEC) domains. Processing of nascent SVMP involves removal of signal-peptide/pre-domain (①) hydrolysis of the prodomain (②) and disintegrin or disintegrin-like/cysteine-rich domains (③), cyclization of amino-terminal glutamyl residues to pyro-glutamate (④), glycosylation (represented by stars—⑤), addition of new domains (⑥) or dimerization of protein chains (⑦).
Figure 2Schematic representation of prodomain processing: Antibodies against jararhagin prodomain detected predominantly bands of zymogen molecular mass in secretory cells and processed form in the lumen of the venom gland. Prodomain was poorly detected in the venom, suggesting that SVMPs are mostly in the active form.
Figure 3Cellular localization of prodomains. Venom glands collected before (A) or seven days after (B, C) venom extraction were sectioned and subjected to immunofluorescence (A, B) stained with DAPI (blue) and mouse anti-PD-Jar serum (green), which concentrated in the apical region of secretory cells, or electron microscopy (C) after staining with anti-PD-Jar serum, which highlighted spots in the secretory vesicles [46].
Inhibition of jararhagin activities by its recombinant prodomain (PD-Jar) or a prodomain degradation peptide (SynPep).
| Activity | PD-Jar 1 | SynPep 1 | ||
|---|---|---|---|---|
| Molar Ratio | % Inhibition | Molar Ratio | % Inhibition | |
| Catalytic 2 | 1:10 | 98 | 1:5000 | 90 |
| Fibrinolytic 3 | 1:14 | 100 | 1:200 | 100 |
| Hemorrhagic 4 | 1:9 | 100 | 1:500 | 100 |
1 Values correspond to enzyme to PD-Jar/SynPep molar ratios that resulted in inhibition of jararhagin activity; 2 Inhibition of enzymatic activity was tested by incubation with Abz-A-G-L-A-EDDnp as fluorescence quenched metalloproteinase substrate and compared according to the relative fluorescence units (RFU/min/µg) of each reaction [97]; 3 Inhibition of jararhagin fibrinolytic activity was calculated by measuring the hydrolysis halo in fibrin-containing agarose plates [98]; 4 Hemorrhage levels were calculated by measuring the hemorrhagic area 30 min after intradermal injection in the dorsal region of four mice [98].